Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413657 | PMC |
| http://dx.doi.org/10.1016/j.apsb.2024.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice.
Acta Pharm Sin B
September 2024
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012, China.
Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.
bioRxiv
December 2023
Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ, 08854, USA.
The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral antivirals. The SARS-CoV-2 papain-like protease (PL) is a promising but challenging drug target. In this study, we designed and synthesized 85 noncovalent PL inhibitors that bind to the newly discovered Val70 site and the known BL2 groove pocket.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!